Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis

References

• Armon C. Epidemiology of amyotrophic lateral sclerosis/motor neuron disease. Motor Neuron Disorders, P Shaw, M Strong. Butterworth Heinemann, Philadelphia 2003; 167–206
   Google Scholar
• Traynor B, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis: a population-based study in Ireland, 1996–2000. J Neurol. 2003; 250: 473–9
   PubMed Web of Science ®Google Scholar
• Turner M, Bakker M, Sham P, Shaw C, Leigh P, Al-Chalabi A. Prognostic modeling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002; 3: 15–21
   PubMed Web of Science ®Google Scholar
• Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998; 50: 66–72
   PubMed Web of Science ®Google Scholar
• Hadjikoutis S, Wiles CM. Venous serum chloride and bicarbonate measurements in the evaluation of respiratory function in motor neuron disease. QJM. 2001; 94: 491–5
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Shefner J, Schoenfeld D, Brown RJ, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003; 61: 456–64
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Shefner J, Schoenfeld D, Zhang H, Andreasson K, Rothstein J, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. 2006; 60: 22–31
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology. 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• Qureshi M, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis. 2006; 7: 173–82
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx. 2004; 1: 284–94
   PubMedGoogle Scholar
• Breslow N, Day N. Statistical Methods in Cancer Research. Intl Agency for Research on Cancer, Lyon 1987
   Google Scholar
• Rothman K. No adjustments are needed for multiple comparisons. Epidemiology. 1990; 1: 43–6
   PubMedGoogle Scholar
• Szekely C, Thorne J, Zandi P, Ek M, Messias E, Breitner J, et al. Non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004; 23: 159–69
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. NSAIDs and Alzheimer's disease: epidemiological, animal model and clinical studies. Neurobiology of Aging. 2007; 28: 639–47
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurology. 2007; 6: 1045–53
   PubMed Web of Science ®Google Scholar
• Popat RA, Tanner CM, Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2007; 8: 157–63
   PubMed Web of Science ®Google Scholar
• Bilak M, Wu L, Wang Q, Haughey N, Conant K, St Hillaire C, et al. PGE-2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Annals of Neurology. 2004; 56: 240–8
   PubMed Web of Science ®Google Scholar
• Zhao W, Xie W, Xiao Q, Beers D, Appel S. Protective effects of an anti-inflammatory cytokine, interleukin-4, on motor neuron toxicity induced by activated microglia. Journal of Neurochemistry. 2006; 99: 1176–87
   PubMed Web of Science ®Google Scholar
• Shaheen SO, Sterne JAC, Songhurst CE, Burney PGJ. Frequent paracetamol use and asthma in adults. Thorax. 2000; 55: 266–70
   PubMed Web of Science ®Google Scholar
• Dimova S, Hoet PHM, Nemery B. Paracetamol (acetaminophen) cytotoxicity in rat type II pneumocytes and alveolar macrophages in vitro. Biochemical Pharmacology. 2000; 59: 1467–75
   PubMed Web of Science ®Google Scholar
• Yasui M, Yoshida M, Tamaki T, Taniguchi Y, Ota K. Similarities in calcium and magnesium metabolism between amyotrophic lateral sclerosis and calcification of the spinal cord in the Kii Peninsula ALS focus. Brain & Nerve. 1997; 49: 745–51
   PubMedGoogle Scholar
• Oyanagi K, Kawakami E, Kikuchi-Horie K, Ohara K, Ogata K, Takahama S, et al. Magnesium deficiency over generations in rats with special references to the pathogenesis of the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Neuropathology. 2006; 26: 115–28
   PubMed Web of Science ®Google Scholar
• Oyanagi K. The nature of the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam and magnesium deficiency. Parkinsonism & Related Disorders. 2005; 11(Suppl 1)S17–23
   Google Scholar
• Lacomblez L, Bensimon G, Leigh P, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group. N Engl J Med. 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Miller R, Mitchell J, Lyon M, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Neuromuscular Disease Group Cochrane Database of Systematic Reviews. 2004; 2.
   Google Scholar
• Edwards I, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007; 30: 515–25
   PubMed Web of Science ®Google Scholar
• Chong P, Boskovich A, Stevkovic N, Bartt R. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy. 2004; 24: 1194–203
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006; 166: 1519–24
   PubMedGoogle Scholar
• Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004; 63: 1933–5
   PubMed Web of Science ®Google Scholar
• Caroscio J, Mulvihill M, Sterling R, Abrams B. Amyotrophic lateral sclerosis: its natural history. Neurologic Clinics. 1987; 5: 1–8
   PubMed Web of Science ®Google Scholar